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Abstract
Magnetic resonance imaging provides a unique tool for in vivo visualization and tracking of stem cells in the brain. This is of
particular importance when assessing safety of experimental cell treatments in the preclinical or clinical setup. Yet, specific
imaging requires an efficient and non-perturbing cellular magnetic labeling which precludes adverse effects of the tag, e.g. the
impact of iron-oxide-nanoparticles on the critical differentiation and integration processes of the respective stem cell population
investigated. In this study we investigated the effects of very small superparamagnetic iron oxide particle (VSOP) labeling on
viability, stemness and neuronal differentiation potential of primary human adult neural stem cells (haNSCs). Cytoplasmic VSOP
incorporation massively reduced the transverse relaxation time T2, an important parameter determining MR contrast. Cells
retained cytoplasmic label for at least a month, indicating stable incorporation, a necessity for long-term imaging. Using a clinical
3T MRI, 1x103 haNSCs were visualized upon injection in a gel phantom, but detection limit was much lower (5x104 cells) in layer
phantoms and using an imaging protocol feasible in a clinical scenario. Transcriptional analysis and fluorescence
immunocytochemistry did not reveal a detrimental impact of VSOP labeling on important parameters of cellular physiology with
cellular viability, stemness and neuronal differentiation potential remaining unaffected. This represents a pivotal prerequisite with
respect to clinical application of this method.
  
 Contribution to the field
Dear academic editor, Dear reviewing colleagues, this cover letter accompanies our manuscript “A safe and effective magnetic
labeling protocol for MRI-based tracking of human adult neural stem cells”. After the discovery of the therapeutic potential exerted
by embryonic and adult stem cell populations, researchers and clinicians started to develop cell-based therapeutic approaches for
degenerative neurological disorders which have been considered untreatable for decades. Adult neural stem cells are of particular
importance for this field of regenerative medicine, as these cells can be applied relatively broad in allogeneic or even autologous
settings. Magnetic Resonance Imaging (MRI)-based tracking of stem cell populations upon transplantation into the human brain is a
non-invasive and hence essential safety and efficacy readout for a broad variety of experimental neurological treatments. The
precise information obtained allows to ensure maximum patient safety and at the same time to collect ample information on
therapeutic efficacy in serial investigations, but requires an iron oxide labeling of transplanted cells. While appropriate protocols
exist for embryonic and fetal neural stem cells, a safe and efficient labeling procedure has not been reported for their
post-partum human counterparts before. Here, we describe a highly efficient labeling protocol for human adult neural stem cells
using very small superparamagnetic iron oxide particle. Next to reporting the detailed procedure, we can show that the protocol
does not affect cell viability, proliferation and differentiation potential and results in excellent detectability in low-field clinical
scanners. Importantly, the application of lipofection agents, most of which cannot be applied in clinical setting, is not necessary
using our protocol. We believe that this paper has a good impact on the emerging field of clinical cell transplantations for
neurological disorders. It is of particular interest for a broad community of translational researchers including chemists, cell
biologists, neuroscientists, as well as clinician-researchers. Hence, making our results available to such a broad community
requires a multidisciplinary journal, making Frontiers in Neuroscience our first choice. We do look to the results of your expert
appraisal of our manuscript as well as both critical and constructive reviewer comments that will help to improve our manuscript.
Sincerely yours, Albrecht Stroh
  
I r
ew
  
 Ethics statements
 Studies involving animal subjects
Generated Statement: The animal study was reviewed and approved by Landesuntersuchungsamt Rheinland Pfalz.
  
 Studies involving human subjects
Generated Statement: The studies involving human participants were reviewed and approved by Ethik Kommission Universität
Erlangen. The patients/participants provided their written informed consent to participate in this study.
  
 Inclusion of identifiable human data
Generated Statement: No potentially identifiable human images or data is presented in this study.
In revi
ew
  
 Data availability statement
Generated Statement: The datasets generated for this study are available on request to the corresponding author.
  
In revi
ew
1 
 
Title page 1 
 2 
A safe and effective magnetic labeling protocol for  3 
MRI-based tracking of human adult neural stem cells 4 
 5 
Albrecht Stroh1,* Jenny Kressel2,3, Roland Coras4, Antje Y. Dreyer5, Wenke Fröhlich5, 6 
Annette Förschler2, Donald Lobsien6, Ingmar Blümcke4, Saida Zoubaa7, Jürgen Schlegel7, 7 
Claus Zimmer2, Johannes Boltze5,8 8 
 9 
1Institute for Pathophysiology, Mainz University, Germany 10 
2Department of Neuroradiology, Technical University Munich, Germany 11 
3Institute for Biological and Medical Imaging, Helmholtz Center Munich, Germany 12 
4Department of Neuropathology, University Hospital Erlangen, Germany 13 
5Fraunhofer Institute for Cell Therapy and Immunology and Translational Center for 14 
Regenerative Medicine, University of Leipzig, Germany 15 
6Department of Neuroradiology, University Hospital Leipzig, Leipzig, Germany 16 
7Division of Neuropathology, Institute of Pathology, Technical University Munich, Germany 17 
8School of Life Sciences, University of Warwick, Coventry CV4 7AL, United Kingdom 18 
 19 
*Address for correspondence: 20 
Prof. Dr. Albrecht Stroh 21 
Institute for Pathophysiology 22 
Johannes Gutenberg-University Mainz 23 
Hanns-Dieter-Hüsch-Weg 19, 55128 Mainz, Germany 24 
email:  albrecht.stroh@unimedizin-mainz.de;  25 
phone:  +49 6131 39-21347  26 
fax:  +49-6131-17-8073 27 
28 
I r vi
w
2 
 
Abstract 29 
Magnetic resonance imaging provides a unique tool for in vivo visualization and 30 
tracking of stem cells in the brain. This is of particular importance when assessing safety of 31 
experimental cell treatments in the preclinical or clinical setup. Yet, specific imaging requires 32 
an efficient and non-perturbing cellular magnetic labeling which precludes adverse effects of 33 
the tag, e.g. the impact of iron-oxide-nanoparticles on the critical differentiation and 34 
integration processes of the respective stem cell population investigated. In this study we 35 
investigated the effects of very small superparamagnetic iron oxide particle (VSOP) labeling 36 
on viability, stemness and neuronal differentiation potential of primary human adult neural 37 
stem cells (haNSCs). Cytoplasmic VSOP incorporation massively reduced the transverse 38 
relaxation time T2, an important parameter determining MR contrast. Cells retained 39 
cytoplasmic label for at least a month, indicating stable incorporation, a necessity for long-40 
term imaging. Using a clinical 3T MRI, 1x103 haNSCs were visualized upon injection in a gel 41 
phantom, but detection limit was much lower (5x104 cells) in layer phantoms and using an 42 
imaging protocol feasible in a clinical scenario. Transcriptional analysis and fluorescence 43 
immunocytochemistry did not reveal a detrimental impact of VSOP labeling on important 44 
parameters of cellular physiology with cellular viability, stemness and neuronal 45 
differentiation potential remaining unaffected. This represents a pivotal prerequisite with 46 
respect to clinical application of this method.  47 
48 
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Introduction 49 
Stem cell transplantation represents one of the most promising strategies for the 50 
restoration of lost cells or tissue including their functions, or at least for delaying the 51 
pathogenic progress in neurodegenerative diseases[1]. The question whether adult or 52 
embryonic stem cells are best suited for clinical applications remains open3,4, yet adult stem 53 
cells show reduced probability of teratoma formation, and thereby represent a promising 54 
candidate for clinical translation[2; 3]. In humans, adult neural stem cells are present in the 55 
subventricular zone and in the subgranular zone of the hippocampal dentate gyrus5–7. These 56 
cells can be isolated from patients with intractable temporal lobe epilepsy subjected to 57 
neurosurgical intervention8. Stem cells tracking and long term monitoring is demanded for 58 
thorough development of safe and efficient transplantation protocols and to further our 59 
understanding about therapeutic modes of action in both the preclinical and clinical setting.  60 
To date, magnetic resonance imaging (MRI) of magnetically labeled stem cells 61 
represents the only clinically applicable imaging method for highly-sensitive, non-invasive 62 
detection and long-term tracking of transplanted stem cells over extended periods of time[4; 5; 63 
6]. Citrate-coated very small superparamagnetic iron oxide particles (VSOP) are widely used 64 
for pre-transplantation stem cell labeling. These particles are incorporated via endocytosis, 65 
aggregate and ultimately get stored in intracytoplasmic vesicles[5; 7]. Incorporation of VSOP 66 
can be enhanced by lipofection to enhance the percentage of strongly labeled cells[8]. 67 
Superparamagnetic iron oxide particles also seem to be biodegradable[9] and can even be 68 
utilized by the cells in iron metabolism pathways[10].  69 
However, the incorporation of iron oxide particles may lead to distinct changes in 70 
stem cell physiology[11; 12; 13; 14]. Moreover, superparamagnetic iron oxide/poly-L-lysine-71 
labeling of a mouse neural stem cell line was reported to induce changes in expression of 72 
genes responsible for iron homeostasis, despite apoptotic pathways were not upregulated in 73 
that particular study[15]. Further, iron oxide particles have been shown to cause transient 74 
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oxidative stress, closely linked to the free iron during incubation[14] and most likely due to 75 
degradation and release of ferric ions into the acidic endolysosomal compartments[16]. Thus, 76 
evaluating the safety and impact of VSOP labeling on the differentiation potential of highly 77 
sensitive human adult stem cells is an important prerequisite for clinical translation[17]. 78 
Finally, the intended labeling protocol needs to be tailored to the respective stem cell 79 
population to ensure an acceptable balance between labeling intensity/efficacy and safety[18]. 80 
Our study investigates describe the long term efficacy of human adult human neural 81 
stem cell (haNSC) VSOP labeling and its impact on viability, expansion, and neuronal 82 
differentiation potential for the first time. We analyzed both non-differentiated haNSCs as 83 
well as mature haNSCs-derived neurons, with murine embryonic stem cells (mESC) serving 84 
as cellular controls. We also assessed cell detection limit in in vitro MRI with different 85 
modalities including one being close to a potential clinical application.  86 
87 In revi
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Results 88 
Safety of cell labeling with VSOP  89 
To assess safety of haNSC preparation, cryopreservation, and labeling (0.5 mM), or to 90 
detect any donor-dependent differences, cell viability was tested in the first step. No 91 
significant donor-dependent differences in cell viability between cells which underwent the 92 
labeling procedure with 0.5 mM (85-89%) and non-labeled control cells (91%, sample pooled 93 
from all patients) could be detected one day after labeling (Fig. 1a). All samples could be 94 
included in onward experiments according to preset viability criteria (>80%). Next, cell 95 
viability of haNSCs and mESCs was compared 8 and 48 hours after labeling with 0.5 and 1.5 96 
mM VSOP, respectively (Fig. 1b). Again, no significant differences in haNSCs viability 97 
between non-labeled control cells (95%), as well as 8 (87.5%) and 48 hours (94.5%) after 98 
labeling became apparent. Viability of mESCs decreased slightly to 89% at 8 hours and to 99 
93.5% at 48 hours after labeling. No viability differences were observed between 0.5 and 1.5 100 
mM VSOP concentration.  101 
 102 
Efficacy of magnetic cell labeling  103 
Incubation of haNSCs with 0.5 mM VSOP alone (“simple”) and additional lipofection 104 
resulted in a substantial uptake of magnetic label (Fig. 2). Prussian blue staining revealed a 105 
homogenous ferric ion distribution in the cytoplasm, excluding the nuclei (Fig. 2a and 2b). 106 
Prussian blue signals remained unchanged from day 2 to day 28 post simple incubation (Fig. 107 
2c and 2d), indicating a stable vesicular incorporation of VSOP for at least one month. This 108 
ratio did not differ significantly between day 2 and day 28. No apparent increase in iron-oxide 109 
particle uptake was observed upon visual inspection in lipofected cells (Fig. 2e to 2f), which 110 
was confirmed by counting labeled cells. Overall, 96-100% of haNSCs were labelled. 111 
Labeling efficacy could not be improved significantly at any time point by additional 112 
lipofection (+L) (Fig. 2g), so lipofection was omitted in all further experiments. 113 
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Proliferation assays 114 
We next conducted a proliferation assay of labelled and non-labelled haNSCs. Over 115 
the course of 8 days, an exponential increase in cell number could be observed, yet, notably, 116 
no significant difference could be detected between the proliferation curves on non-labelled 117 
and haNSCs incubated with 0.5 and 1.5 mM VSOP (Fig. 2 h).  118 
 119 
Magnetic resonance properties 120 
Next, the impact of 0.5 and 1.5 mM VSOP-labeling of both stem cell populations on 121 
magnetic resonance properties was determined after 8 and 48 hours via NMR relaxometry 122 
(Fig. 3a and 3b). Unlabeled cells had a T2 time of 2110 ms (mESCs) and 1948 ms (haNSCs), 123 
revealing no significant difference between both protocols. In contrast, VSOP-labeling with 124 
0.5 mM and 8 hours incubation time led to a significant reduction of T2 time to 10% of 125 
control values (mESCs: 218 ms, haNSCs: 227 ms, Fig. 3a, P<0.01). 48 hours after incubation, 126 
T2 time ranged at 15% of control values (mESCs: 298 ms, haNSCs: 408 ms, Fig. 3b). Further 127 
increasing VSOP concentrations to 1.5 mM resulted in an additional reduction of average T2 128 
time which, however, was not statistically significant from that after 0.5 mM incubation.  129 
 130 
In vitro MR imaging 131 
To assess clinical applicability of the labeling protocol, gradient echo MR images of 132 
gel phantoms with injected cells were acquired (Fig. 3c to 3g). On the T2*-weighted images 133 
two needle tracks on the gel surface can be delineated as hyperintense signal changes (Fig. 3c) 134 
in injection phantoms. On the left side of the phantom 1x103 magnetically labeled haNSCs 135 
were injected, whereas 1x103 unlabeled control haNSCs where placed on the right side. The 136 
T2*-weighted images clearly showed hyperintense signal changes only in the left injection 137 
track deposit of 1x103 labeled haNSCs (Fig. 3d and 3e). Cell detectability was lower in layer 138 
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phantoms imaged at 3T SWI with a protocol that could be applied on hypothetical patient. 139 
Only 5x104 labelled cells were detectable with the applied imaging protocol (Fig. 3f and 3g). 140 
 141 
Characterization of non-differentiated VSOP labeled stem cells 142 
Cells were magnetically labeled and subsequently analyzed by RT-PCR and Western 143 
Blotting (Fig. 4a). Non-labeled haNSCs and mESCs served as cellular controls. After 144 
culturing in the appropriate expansion media, all cells except the HT22 expressed the mRNA 145 
for the stemness markers Oct4 and Sox2, and the neural progenitor marker nestin. haNSCs 146 
and mESCs loaded with 0.5 mM VSOP (VSOP) or VSOP plus lipofection agent (VSOP+L) 147 
revealed the same mRNA expression pattern. No difference between stem cells incubated 148 
with (L) and without lipofectin became apparent. 149 
Analysis of haNSCs using fluorescent immunocytochemistry showed that 99% of cells 150 
express the intermediate filament protein nestin (Fig. 4b). 65% co-expressed the nuclear 151 
proliferation marker Ki-67 (Fig. 4C-D). 99% of haNSCs, which underwent the VSOP-152 
labeling procedure and subsequently had a high cytoplasmatic iron loading, expressed nestin 153 
while 64% of cells were found positive for Ki-67 (Fig. 4e to 4g). Substantial differences 154 
between control cells and VSOP labeled haNSCs from all three donors could not be observed 155 
(Fig. 4h). Analysis of nestin and Ki-67 co-expression revealed no impact of VSOP labeling 156 
(Fig. 4i). However, we found a significant effect on relative numbers of cells co-expressing 157 
nestin and Ki-67 in the three patients (P<0.01).  158 
 159 
Differentiation potential of VSOP-labeled stem cells  160 
Fig. 4j illustrates the analysis of stem cells that were magnetically labeled and 161 
subsequently neuronally differentiated over 15 days. Non-labeled, but neuronally 162 
differentiated haNSCs and mESCs served as controls. To characterize the transition from 163 
neural progenitors to mature neurons, mRNA expression levels of β-tubulin III, doublecortin 164 
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(DCX), neural cell adhesion molecule 1 (NCAM-1) as well as microtubule associated 165 
phosphoprotein 2 (MAP-2) were investigated. RT-PCR analysis indicated neural progenitors 166 
and immature neurons in control cell populations as well as in magnetically loaded cell 167 
populations. No differences in expression patterns were observed.  168 
169 
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Discussion 170 
In this study, we were able to show that labeling of haNSC with iron-oxide-particles, 171 
required for a high-resolution MR Imaging, is both safe and efficient. Labeling efficiency 172 
using 0.5 mM VSOP was found up to 100% and resulted in stable cell labeling for at least one 173 
month. Trypan blue exclusion tests at different time points and comparison of different patient 174 
samples demonstrated that VSOP-labeling had no effect on overall haNSCs viability. Using 175 
clinical 3T MRI, we visualized 1x103 labeled cells in an injection phantom, modeling the in 176 
vivo situation under optimal imaging conditions. Moreover, 3T SWI MRI of layer phantoms 177 
with layers containing up to 5x104 labelled cells was performed, applying an imaging protocol 178 
taking 41:00 minutes. This is short enough to be applied in a hypothetical clinical scenario, 179 
but on the upper limit what could be performed in critically ill patients. The protocol settings 180 
were chosen on optimal detectability in VSOP-labelled mesenchymal stem cells [24]. The 181 
analysis of Oct4 and Sox2 mRNA-expression in addition to the quantitative fluorescence 182 
immunocytochemistry analysis of Ki-67 and nestin co-expression as stem cell markers and 183 
indicators of proliferation activity showed no impact of VSOP labeling, but significant 184 
differences in haNSC samples from different donors. Furthermore, neuronal differentiation 185 
potential and neuronal marker expression were not affected by the labeling procedure. 186 
Prussian blue staining resulted in a homogenous ferric ion distribution in the 187 
cytoplasm, but not in the nucleus. This is in line with previous findings from our group, 188 
showing a direct relation between VSOP incubation, intracellular iron load as measured by 189 
atomic absorption spectroscopy, and T2 time reduction[5]. Prussian blue staining was found 190 
stable after 48 hours and 28 days, indicating a transfer of VSOP onto daughter cells during 191 
cytokinesis for proliferating cells. Our data indicate no difference in labeling efficiency and 192 
stability between incubation with VSOP and additional lipofection. One explanation of the 193 
efficient incorporation with VSOP alone could be the small diameter and the negative surface 194 
charge of the citrate coating, already allowing efficient uptake without additional lipofection. 195 
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Albeit lipofection did not raise a safety concern in our study, off-target effects and immune 196 
response caused by transfection reagents have been described[19]. Thus, sufficient labeling 197 
with VSOP but omitting lipofection may represent a clear advantage for subsequent in vivo 198 
and clinical applications.   199 
It is known that citrate coating may interact with the extracellular domain of integrins 200 
and triggers their activation and subsequently intracellular signaling cascades[20]. 201 
Furthermore, VSOP can induce increased levels of transferrin receptor-1. VSOP incubation 202 
can also result in a fast increase and high level of reactive oxygen species (ROS), most likely 203 
due to degradation and release of ferric ions into the acidic endolysosomal compartments[16]. 204 
Although no detrimental influence has been shown in the present study, the overall impact of 205 
these potential alterations should be carefully controlled after in vivo transplantation. While 206 
measures of T2 relaxation times provide an indication of the cellular iron uptake, a direct 207 
measure of iron content, as conducted in previous studies of ours using the same iron-oxide 208 
particles, yet in different cells, would be desirable [5; 6]. We were not able to conduct these 209 
assays due to the scarcity of the cellular material. Also, iron-oxide particles have shown to 210 
induce oxidative stress [14], potentially leading to oxidative damage to proteins, lipids and 211 
even DNA, also at low concentrations of the label [21]. Viability assays, as conducted here, 212 
might not be sensitive towards these molecular changes, but again, we were not able to 213 
conduct these assays due to the limited availability of the cells.   214 
 215 
 216 
Potential effects of iron oxide on the neuronal differentiation potential of haNSC and 217 
mESC, were analyzed on the gene transcription level. The present data indicates that VSOP-218 
labeled haNSCs and mESCs can be expanded without affecting their potential for both 219 
neurogenesis, as represented by the pluripotency markers Sox2 [22] and Oct4[23], or their 220 
ability for neuronal differentiation. Magnetic labeling had also no impact on mRNA 221 
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transcription of nestin and Ki-67 expression even after 14 days in culture. In this study, we 222 
used iron-oxide nanoparticles, which are presumably taken up by the cells by endocytosis 223 
[14]. This means, that in contrast to genetically encoded labels, the concentration of particles 224 
in the cells will diminish over time, both due to cell proliferation, and also due to particle 225 
degradation. This limits the time window, in which these cells will be detectable by MRI. 226 
What is more, we provided data on RNA level on the differentiation potential of these 227 
labelled cells, but this does not prove a functional stable differentiation into a given neuronal 228 
subtype. For that, additional assays on protein level and ultimately electrophysiological 229 
evidence need to be conducted [24]. 230 
 231 
1x103 VSOP-labeled haNSC were easily identified in a gel phantom, reliably 232 
modeling the situation upon stereotactic transplantation in vivo[5]. This detection range is 233 
more than sufficient to monitor cell migration in clinical scenarios where 20 to 300x103 or 234 
even more cells are transplanted [25; 26]. Nevertheless, the detection limit is rather high 235 
compared to other studies that repeatedly shown single cell detectability. A direct comparison 236 
is difficult though. For instance, some studies employed ultra-high field strengths (11.7T) and 237 
imaging protocols optimized for that purpose [27]. Others used long imaging times and 238 
different cell types such MDA‐MB‐231BR breast cancer cells or J774 macrophages [28]. Both 239 
cell types are much larger (up to 25 µm diameter and up to 100 µm in length for 240 
MDA‐MB‐231BR) than neural stem cells and therefore can store much higher amounts of 241 
VSOP, while macrophages are particularly efficient in uptaking VSOPs. We also had to apply 242 
relatively long scanning times to visualize 1x103 labelled cells. Moreover, ultra long-term in 243 
vivo imaging at 3T may necessitate higher cell concentrations as cell loss or dilution of 244 
intracellular iron content due to in vivo proliferation may reduce the overall signal obtained. It 245 
should be noted though that cell detectability is different in gel phantom and in vivo imaging, 246 
the latter commonly associated with higher detection limits. 247 
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On the other hand, 3T SWI with a short-term protocol optimized for cell detectability 248 
was only able to detect 5x104 cells in a layer phantom, modelling wide-spread cell 249 
distribution as can be observed after systemic transplantation or migration. Apart from the 250 
shorter imaging time and the lower number of averages, the higher detection limit might have 251 
two potential reasons. First, layer phantoms represent the cell distribution seen after systemic 252 
(intraarteriell or intravenous) cell injection. Systemic cell injection is believed to be more 253 
feasible for clinical applications and is therefore used predominantly in ongoing clinical trials 254 
[29]. The density of cells is lower than in injection phantoms that represent the situation after 255 
stereotactic cell implantation procedures, being reserved for a targeted approach requiring 256 
local cell deposits. Second, the imaging protocol applied for layer phantom imaging was 257 
developed for mesenchymal stem cells which are larger than haNSCs and might therefore 258 
incorporate more VSOP leading to better detectability. 7T MRI, which is being introduced 259 
into clinical imaging, and allowing for detection of small local concentrations of labeled cells 260 
while the feature of VSOP to further reduce the longitudinal (T1) and transverse (T2) 261 
relaxation time may provide much better cell detectability at high filed strengths in future 262 
applications [30].  263 
In summary, our study strongly suggests that in the clinical setting, cell tracking using 264 
magnetic VSOP labeling represents a safe method, capable of addressing three key issues 265 
vital for effective transplantation strategies: location, migration, and viability.  266 
267 
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Methods 268 
Ethical Statement 269 
Human adult neural stem cells were obtained from patients with temporal lobe 270 
epilepsy submitted to epilepsy surgery. Informed and written consent was given for additional 271 
scientific investigations approved by the local ethics committee of the University of Erlangen, 272 
in accordance with the Declaration of Helsinki. 273 
 274 
Human adult neural stem cell and murine embryonic stem cell cultures 275 
Composition of expansion and differentiation media is given in Table 1. After surgical 276 
en bloc resection, the dentate gyrus was micro-dissected and dissociated mechanically 277 
followed by enzymatic digestion as described previously8. Of the obtained cells, haNSC from 278 
passage 5 to 11 were cryopreserved, shipped to the primary investigation site and used for all 279 
experiments. Cells were plated on poly-L-ornithine (250 µg/mL)-/laminin (15 µg/mL, both 280 
Sigma-Aldrich, Munich, Germany)-coated cell culture dishes (Sarstedt, Nuembrecht, 281 
Germany) and grown in expansion medium at 37°C and 5% CO2. Medium was changed every 282 
second day. Cells were detached with accutase (PAA, Cölbe, Germany) at 80% confluence, 283 
and split. Culturing over at least five passages selected for proliferating cells. 284 
Previously cryopreserved mouse embryonic stem cells (mESCs, CRL-1934, ATCC, 285 
Manassas, USA) were cultured in expansion medium (Table 1) at 37°C and 5% CO2 on 286 
mouse fibroblasts (CRL-1503, ATCC, Manassas, USA) inactivated by mitomycin C (Sigma-287 
Aldrich). Stem cells were separated from the fibroblast layer at 60% confluence by detaching 288 
them with accutase, and transferred to gelatin-coated cell culture dishes with daily medium 289 
changes. mESCs were detached and transferred every other day. A fibroblast-free mESCs 290 
culture was obtained after three passages. 291 
  292 
Magnetic cell labeling and viability assessment  293 
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Sterile VSOP (C200, Ferropharm, Teltow, Germany), consisting of a 5nm iron oxide 294 
core coated with monomer citrate, resulting in a hydrodynamic diameter of 11 nm and a 295 
negative charge were used for labeling at 0.5 and 1.5 mM with or without additional 296 
lipofection agent (lipofectin, Invitrogen) for 4 hours as described previously17. These 297 
molarities were chosen based on previous findings showing that VSOP labelling causes 298 
transient oxidative stress or even irreversible cell damage [6; 14]. Transient oxidative stress is 299 
already observed at 1.5 mM, and higher incubation molarities such as 3.0 mM or 6.0 mM 300 
cause more intensive stress or even increase apoptosis and necrosis. In turn, higher VSOP 301 
incubation molarities not necessarily shortens T2 relaxation times or increases detectability, 302 
particularly in smaller cells [6].  303 
Control specimens were incubated in Opti-MEM I for 4 hours instead. First, potential 304 
donor-specific viability differences were assessed 20 hours after labeling with 0.5 mM VSOP. 305 
Only cells samples with >80% viability after labeling were defined acceptable for further 306 
investigation. Next, cell viability in relation to incubation molarities was assessed 8 and 48 307 
hours after VSOP incubation by the Trypan Blue (Sigma-Aldrich) exclusion test on 10 308 
randomly selected regions per coverslip. 309 
 310 
Labeling efficacy assessment and haNSC proliferation experiments 311 
Uptake of VSOP was evaluated using Prussian blue staining 48 hours and 28 days 312 
after VSOP labeling by phase contrast microscopy of 10 regions per coverslip. The relative 313 
labeling efficacy was displayed as a ratio of Prussian blue positive cells to all cells identified 314 
by nuclear counterstaining.  315 
 After labeling with 0.5 µM or 1.5µM VSOP (see above), haNSCs were seeded on 12-316 
well-plates covered with poly-L-ornithine-covered (Sigma-Aldrich) at a density of 7,500 317 
cells/cm2 (28,500 cells/well) on expansion medium. Unlabelled haNSCs served as controls. 318 
Proliferation of haNSCs was monitored over 8 days, and cell culture medium was exchanged 319 
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every second day. Cell numbers were assessed on days 1, 2, 4 and 8 in three wells for each 320 
VSOP concentration and on each day. Experiments were performed with using a total of six 321 
haNSC lines derived from three different patients (n=3). 322 
 323 
NMR relaxometry 324 
Further, nuclear magnetic resonance (NMR) relaxometry was performed to determine 325 
the T2 time (transverse relaxation time). 9x105 cells were suspended in 3 mL PBS and 326 
measured in a NMR-Relaxometer Minispec 0.47T/20MHz (Bruker, Ettlingen, Germany). 327 
Data analysis was performed using the ORIGIN Pro 8G software (OriginLab Corporation, 328 
Northampton, USA). All samples have been analyzed in three independent experiments. 329 
 330 
Clinical MR imaging at 3 Tesla 331 
Detectability of VSOP labeled haNSCs was assessed by in vitro MRI. Two different 332 
types of agarose gel phantoms, cell injection and cell layer phantoms, were used. For injection 333 
phantoms, 1x103 magnetically labeled haNSCs (1.5 µM VSOP) were injected into air bubble-334 
free gel phantoms as described previously16. Briefly, 1x103 magnetically labeled haNSCs 335 
were injected on one side of the phantom, and 1x103 non-labeled haNSCs on the other.  336 
Injection phantom MRI was performed on a clinical 3 Tesla scanner (Achieva 3T, 337 
Philips Medical Systems, Best, The Netherlands) under conditions optimized for cell imaging. 338 
A 3T solenoid rat coil (RX SN 1116, Philips) with a coil diameter of 55 mm was used. 2D 339 
gradient echo sequences were applied, with TE / TR 13.8 / 50 ms, a flip angle of the 340 
excitation pulse of 15°, yielding images that were T2* (effective transverse relaxation time) 341 
weighted. Both a coronal as well as a sagittal data set was acquired covering the entire gel 342 
phantom. The slice thickness was 0.3 mm, the interslice distance 0.15 mm, with a 20 mm 343 
field of view, and a 288x288 matrix, resulting in an inplane resolution of 69 µm and a voxel 344 
size of 69x69x300 µm3.  345 
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Layer gel phantoms were produced as described elsewhere [31]. Two phantoms were 346 
produced, each containing four layers in which unlabeled or VSOP-labeled haNSCs (1.5 µM) 347 
were embedded. Layer phantom 1 contained layers with 5x10, 1x102, 5x102 and 1x103 VSOP-348 
labeled haNSCs, respectively. Layer phantom 2 contained layers with 5x103, 1x104, and 349 
5x104 VSOP-labeled haNSCs, as well as a layer containing 5x104 unlabeled haNSCs.  350 
Layer phantom MRI was performed on a clinical 3 Tesla Scanner (Magnetom Trio, 351 
Siemens, Erlangen, Germany) equipped with a standard 8ch knee coil. The imaging protocol 352 
was not particularly optimized for cellular imaging but rather to reflect a clinical situation. 3D 353 
Susepctibility-weighted images (SWI) were obtained with TE / TR 20 / 60 ms at a flip-angle 354 
FA of 15°. A voxel size of 560x490x250 µm3 was achieved. Acquisition time TA was 41:00 355 
min. SWI sequences were processed by vendor-specific software of the MRI scanner (Syngo 356 
B15, Siemens, Erlangen, Germany) and analyzed without further post-processing.  357 
 358 
RT-PCR analysis 359 
Cells were harvested before and after magnetic labeling, and neuronal differentiation 360 
(see below), respectively. RNA species >200 nt were extracted using Mini RNeasy kit. cDNA 361 
synthesis with integrated removal of genomic DNA contamination was performed on 1 µg 362 
RNA using QuantiTect Reverse Transkription kit (both Qiagen, Hilden, Germany). PCR was 363 
performed on 2 µl of cDNA using Taq-DNA-Polymerase all inclusive kit (Peqlab, Erlangen, 364 
Germany). Table 2 shows the primer sequences used in this experiment. All samples were 365 
analyzed in at least three independent experiments. Mature mouse hippocampal cells HT22 366 
were used as a negative control for pluripotency and neural progenitor markers. 367 
 368 
Fluorescence immunocytochemistry and characterization 369 
For characterization of cultured haNSCs and for determining effects of magnetic 370 
labeling on stemness, cells were fixed in PBS-buffered paraformaldehyde (4%). Processing, 371 
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immunocytochemistry and quantitative evaluation were performed as described elsewhere28. 372 
Mouse-anti-Ki67 (Dako, 1:100, proliferation marker), and rabbit-anti-nestin (Millipore, 373 
1:200, neural progenitor cell marker) were used as primary antibodies, and Alexa Fluor 555 or 374 
488 (both Invitrogen, 1:100) served as secondary antibodies. Nuclei were labeled by 4’,6-375 
Diamidino-2-phenylindole dihydrochloride (DAPI, Sigma-Aldrich, 1.1000). For analysis, 10 376 
randomly selected regions per coverslip were counted. Percentage was determined as the 377 
number of nestin+, Ki-67+, or Ki-67+/nestin+ cells compared to total cells identified by nuclear 378 
DAPI counterstaining. 379 
 380 
Neuronal differentiation of haNSCs and mESC 381 
The possible interference of VSOP-labeling or lipofectin on neuronal differentiation 382 
was also assessed. haNSC were differentiated for 15 days in haNSC differentiation medium 383 
(Table 1), which was changed every second day. Six independent experiments were 384 
conducted, containing at least three technical replicates each. 385 
mESCs-differentiation was performed as described elsewhere29 with some 386 
modifications. For embryoid body formation expanded mESCs were transferred into bacterial 387 
dishes and LIF was removed. After 6 days cells had aggregated and formed embryoid bodies, 388 
which were carefully transferred to gelatine-coated dishes. During the following 2-3 days, the 389 
heterogeneous bodies adhered and migrating cells started to form a monolayer. Neural 390 
progenitor cells were selected for 3 days and then expanded in neural progenitor expansion 391 
medium (Table 1) for 10 days. RT-PCR analysis and Prussian blue staining were performed 392 
as described above. Ten independent experiments were conducted. 393 
 394 
Statistical analysis 395 
Statistical analysis was conducted using SPSS (Chicago, IL) software. First, data sets 396 
from all conditions were tested for normal distribution using the parameter free one-sample 397 
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Kolmogorov-Smirnov test. In cases where normal distribution of data was confirmed, the 398 
parametric two-tailed Student’s t-test was employed to compare means. P-values <0.01 were 399 
considered statistically significant. All data are presented as mean ± standard error of the 400 
mean (s.e.m.). 401 
402 
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Figure Legends 520 
 521 
Figure 1: Cell viability of magnetically labeled haNSCs and mESCs (n=3 with 3 522 
technical replicates each). (a) Trypan blue exclusion test showed no significant differences 523 
in viability of three different patient samples (labelling with 0.5mM). (b) Trypan blue 524 
exclusion test 8 and 48 hours after labeling showed no decrease in cell viability due to the 525 
labeling procedure.  526 
 527 
Figure 2: Cytological analysis of magnetically labeled haNSCs (n=3 with 3 technical 528 
replicates each). (a) Unlabeled control cells and (b) intracytoplasmic VSOP uptake by 529 
haNSCs following incubation with 0.5 mM VSOP. (c) to (f) Cells were fixed with 4% 530 
phosphate-buffered saline-buffered paraformaldehyde and intracellular iron was visualized 531 
using Prussian blue staining on day 2 as shown in (c) and (e) and on day 28 as provided in (d) 532 
and (f) after labeling. (g) Cell counting revealed that labeling efficacy at any time point could 533 
not be enhanced significantly by lipofection. (h) Proliferation analysis of VSOP-labeled 534 
haNSC (1.5 mM) revealed no statistically significant difference in the proliferation abilities of 535 
unlabeled haNSC and haNSCs labeled with 0.5 mM VSOP, respectively. Scale bars in (a) to 536 
(f) represent 10 µm. 537 
 538 
Figure 3: NMR relaxometry and gradient echo MR images of gel phantoms containing 539 
haNSCs (n=3 or more). (a) and (b) Efficiency of VSOP-labeling was determined after 8 (a) 540 
and 48 hours (b) using NMR relaxometry. All data were analyzed and presented as mean ± 541 
s.e.m. Differences were considered significant at P<0.01. (c) Coronal section at gel surface 542 
showing two needle tracks as hyperintense signal change. 1x103 VSOP labeled haNSCs were 543 
injected on the left side; on the right side 1x103 unlabeled control haNSCs were injected. (d) 544 
Slice 4.5 mm ventral of (c): In the left injection track an area of signal loss can be visualized, 545 
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due to clusters of magnetically labeled haNSCs. No signal change in the right injection track 546 
was observed. (e) Slice 5 mm ventral of (c): The left injection track again shows an area of 547 
signal loss, no signal change in the right injection track. (f) and (g) layer phantoms 548 
investigated in 3T SWI MRI. Only 5x104 labeled haNSCs were detectable with an imaging 549 
protocol being short enough (41:00 min) to be applicable in a hypothetical clinical scenario. 550 
 551 
Figure 4: Transcriptional and immunohistochemical analysis of stemness and neuronal 552 
differentiation (n=6 to 10). (a) VSOP-labeling and lipofection of non-differentiated stem 553 
cells; RT-PCR analysis of pluripotency markers revealed no impact on stemness, and 554 
transcribed nestin. 99% of haNSCs expressed the intermediate filament protein nestin, and 555 
65% co-express the nuclear proliferation marker Ki-67. No significant difference between 556 
control cells and VSOP labeled haNSCs could be detected. (b) to (d) show unlabeled control 557 
cells, and E-G give the VSOP labeled pendant. (h) Nestin expression of haNSCs from three 558 
different patients was compared, showing that there is neither a significant difference between 559 
patients nor between control cells or labeled cells. (i) 65% of haNSCs co-express nestin and 560 
Ki-67, but significant differences between the three patients become apparent. (j) Subsequent 561 
neuronal differentiation (n=6 to 10) resulted in a neuronal phenotype transcribing β-tubulin 562 
III, doublecortin, N-CAM1, and MAP-2. Mature mouse hippocampal cells HT22 served as a 563 
negative control for pluripotency markers and as a positive control for mature neuronal 564 
markers. Scale bars represent 50 µm. 565 
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